Mechanisms of Immune Checkpoint Inhibitors resistance in Non-small cell lung cancer(NSCLC).
Description
1- Low neo-antigens levels: lack of T-cell recognition
2- Loss β2-microglobulin expression affects T-cell recognition of tumour antigens
3- Impaired IFN-γR signalling pathway: JAK1/2 stop functioning
4- Mutations in Wnt/β-catenin pathway: tumour cell proliferation/survival
5- Mutations in PI3K: increased VEGF levels
6- EGFR/HER-2 mutations: promote cell survival, proliferation, & invasion
1- Defect T-cell induction pathway: ICI resistance
2- VEGF & angiogenesis: tumour cell avoid immune attack
Acknowledgements
References
Brassart-Pasco, S. et al. (2020) ‘Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns Title Immunotherapy in NSCLC: from targeted molecules to resistance patterns Short running title Immunotherapy in NSCLC’, Pharmacogenomics, 21(10), pp. 705–720. Available at: https://doi.org/10.2217/pgs-2020-0021ï.
Get started with this template for freeDon’t start from scratch.
Create professional scientific illustrations quickly and easily, even without any design expertise
- Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
- Create figures that effectively communicate your research in half the time using our editable icons.
- Use our PDB tool to quickly generate and customize protein structures
.gif)
